Domperidone

Financing brings total funds raised to $176M to advance diverse portfolio of high-impact medicines and expand efforts to additional high unmet needs Current portfolio of CinCos include two clinical-stage obesity therapeutics, two Phase 2 gastrointestinal programs and several pre-clinical programs CINCINNATI--(BUSINESS WIRE)-- CinRx Pharma, a hub-and-spoke biotech accelerating high-impact medicines, today announced the closing of a $73 million financing, bringing the total funds raised to $176 million. Participants in the round include prior investors comprised of industry insiders and high-net-worth individuals. To date, CinRx has launched five companies (“CinCos”) focused primarily on cardiovascular, metabolic and gastrointestinal conditions. In addition to its company creation function, CinRx has forged several CINergy partnerships with existing companies. CinRx plans to use the funds to advance development of its existing portfolio programs and assets to expand in key areas of high unmet medical need. “Our early financings totaling $103 million supported the construction and progression of our seven-company portfolio. Notably, this included the formation, advancement and exit of CinCor Pharma ahead of its $1.8 billion acquisition, underscoring the success of our incredibly effective team and validation of our efficient business model,” said Dr. Jon Isaacsohn, Founder and Chief Executive Officer at CinRx Pharma. “With this infusion of capital, we will continue rapid advancement of existing programs and replicate our proven asset selection process to identify and accelerate more promising new programs with high potential to impact patients’ quality of life.” CinRx’s portfolio of CinCos are managed by a lean team of scientific, technical and drug development experts with decades of experience treating patients and supporting thousands of clinical development programs. Each CinCo was created through a rigorous asset selection process to identify novel therapies with the potential to address significant unmet medical needs and meaningfully reduce disease burden for patients. CinCor Pharma was created to advance baxdrostat (CIN-107), a highly selective, oral small molecule inhibitor of aldosterone synthase for the treatment of hypertension and other cardiorenal conditions from a license agreement with Roche in 2019. CinRx led the clinical design and execution of baxdrostat, and was responsible for CinCor’s successful Series A and Series B financings to fund its early development through its $194 million IPO in 2022. In early 2023, CinCor was acquired by AstraZeneca in a deal worth $1.3 billion upfront and an additional $500 million in biobucks. CinFina Pharma is developing a pipeline of four therapies, in-licensed from Janssen Pharmaceuticals, aimed at providing safe, tolerable and durable options for treating obesity. In March 2024, CinFina announced the dosing of the first patients in a Phase 1 trial of CIN-110, a PYY analog. Upcoming milestones include initiation of a Phase 2 study evaluating CIN-109, a novel GDF-15 molecule focusing on body composition and lean body mass preservation, with and without semaglutide. Additional preclinical development is ongoing to support Investigational New Drug (IND) application submissions for CIN-209 and CIN-210, which are both dual-agonists utilizing GLP-1 therapy in combination with the aforementioned mechanisms of action. CinDome Pharma is developing deudomperidone (CIN-102) as a potential safe, chronic treatment for gastroparesis. Deudomperidone is a novel formulation of a well-known dopamine D2/D3 agonist, domperidone. In May 2023, CinDome presented encouraging QT study data at the 2023 Digestive Disease Week (DDW) Conference. CinDome recently raised $40 million in a Series B financing from Perceptive Advisors and CinRx, and is actively enrolling the Phase 2 envision3D study for adults with diabetic gastroparesis, expected to read out in 2025. CinPhloro Pharma is progressing CIN-103, a small molecule for the long-term management of irritable bowel syndrome with diarrhea (IBS-D). CIN-103 is a pulsatile-release formulation of phloroglucinol, an approved therapy in select countries outside of the U.S., modified for sustained exposure and less frequent dosing. In February 2024, CinPhloro dosed the first patients in the Phase 2 enviva study to evaluate the safety, efficacy and tolerability of CIN-103 for IBS-D. CinPhloro is actively enrolling the enviva study, which is expected to complete in 2025. About CinRx Pharma: CinRx Pharma is a biotech company advancing a diverse portfolio of high-impact medicines through clinical development with a unique hub-and-spoke business model. CinRx’s approach combines financing with the efficient progression of therapeutic candidates within its portfolio, each managed by CinRx’s central infrastructure and operating team. Current CinCos address areas of high unmet medical need including metabolic, gastrointestinal and oncology. Differentiated by an asset selection process agnostic to therapeutic area, a strategic CRO partnership, and insights from thousands of development programs, CinRx identifies, funds and accelerates promising drugs with the potential to have the highest impact on patients’ quality of life. CinRx Pharma is headquartered in Cincinnati, Ohio. For more information, please visit or follow the company on X and LinkedIn.

▎药明康德内容团队编辑据创鉴汇不完全统计，上周（5月13日至5月19日）全球大健康领域共披露融资事件29起，总额超67亿元。按照金额划分，亿元及以上融资15起。按照已披露的融资轮次划分，早期融资（B轮以前）11起，中后期融资（B轮及以后）13起。生物医药领域共8家公司获融资，涉及药物类型包含单克隆抗体、蛋白降解疗法、细胞基因疗法等。#01Uniquity Bio完成3亿美元融资关键词：单克隆抗体研发公司最新融资：3亿美元未知轮本轮投资机构：Blackstone Life Sciences5月15日，黑石（Blackstone）集团正式推出Uniquity Bio公司，这是一家专注于免疫学和炎症的临床阶段药物开发公司。该公司针对胸腺基质淋巴细胞生成素（TSLP）的单克隆抗体solrikitug的2期临床试验的IND申请已获得美国FDA许可，并从黑石集团获得高达3亿美元的资金支持，用于推进该药物在多个适应症中的研发。Solrikitug是一种高效的抗TSLP单克隆抗体，能阻止TSLP与其受体的结合。鉴于TSLP在炎症级联反应顶端的主控调节因子地位，solrikitug在广泛的免疫学和炎症疾病中具有潜在的应用价值。Solrikitug最初由默沙东（MSD）公司开发，Uniquity Bio获得了这款抗体疗法的开发权益。#02Lycia Therapeutics完成1.07亿美元C轮融资关键词：新型蛋白降解疗法研发公司最新融资：1.07亿美元C轮本轮投资机构：Alexandria Venture Investments、Blue Owl Healthcare Opportunities、Eli Lilly and Company、Franklin Templeton等5月13日，Lycia Therapeutics宣布完成超额认购的1.07亿美元C轮融资。Lycia Therapeutics是一家细胞外蛋白降解疗法开发公司，以专有的溶酶体靶向嵌合体（LYTACs）平台为核心技术，旨在靶向未开发的细胞外蛋白质组，以开发针对自身免疫性和炎症类难治疾病疾病药物。据悉，本轮融资将用于推进其自身免疫性疾病和炎症性疾病的临床先导项目。Lycia公司由2022年诺贝尔化学奖得主，斯坦福大学的Carolyn Bertozzi教授联合创建。在2021年，Lycia与礼来公司达成高达16亿美元的研发合作，利用LYTAC技术发现、开发和推广靶向创新靶点的蛋白降解疗法，涉及免疫学和疼痛等多个治疗领域。#03Ajax Therapeutics完成9500万美元C轮融资关键词：小分子药物研发公司最新融资：9500万美元C轮本轮投资机构：Boxer Capital、EcoR1 Capital、Eli Lilly and Company、Goldman Sachs Alternatives等5月13日，Ajax Therapeutics宣布完成9500万美元C轮超额认购。融资所得将用于支持Ajax潜在的“First-in-class”II型JAK2抑制剂AJ1-11095的临床开发，用于治疗骨髓纤维化，并推进该公司的骨髓增生性肿瘤（MPN）治疗管线。Ajax Therapeutics是一家应用计算化学和基于结构的技术开发新型血液恶性肿瘤小分子的生物技术公司。AJ1-11095由Ajax设计，使用基于结构的药物设计和大规模计算方法，选择性地结合JAK2激酶的II型构象，与目前批准的所有JAK2抑制剂相比，在疾病修饰方面提供潜在更好的疗效。#04CinDome Pharma完成4000万美元B轮融资关键词：胃肠道疾病药物研发公司最新融资：4000万美元B轮本轮投资机构：CinRx Pharma、Perceptive Advisors5月16日，CinDome Pharma致力于推进胃轻瘫的慢性疗法，该公司今天宣布获得4000万美元的B轮融资。这项资本将支持deudomperidone在二期envision3D研究中招募胃轻瘫患者，为公司进行注册试验做好准备。根据公司提供信息，美国有近1600万成年患者出现胃轻瘫症状，一种可以长期使用的安全且有效的治疗方法仍然是一个重大的未满足需求。CinDome研发的deudomperidone是工程化制剂的D2/D3对抗剂多珀酮，这是全球胃轻瘫的首选治疗方法，但在美国尚未获批。#05济因生物完成数千万人民币天使+轮融资关键词：肿瘤基因与细胞疗法研发公司最新融资：数千万元天使+轮本轮投资机构：天创资本5月15日，济因生物完成了数千万人民币天使+轮融资，由天创资本独家投资。济因生物聚焦通用型细胞与基因治疗产品的开发，拥有iPSC重编程及定向分化、体内靶向递送等技术平台。该公司以体内CAR-T、iPS（诱导多能干细胞）来源CAR-iNK为特色管线，致力于提供患者可及的细胞与基因治疗产品。该公司计划将此轮融资主要用于核心技术平台的优化升级以及体内CAR-T管线的临床阶段工作推进。#06Turbine获投资，推动AI细胞模拟药物研发应用关键词：人工智能药物发现公司最新融资：战略投资本轮投资机构：Accenture Ventures5月16日，Accenture对Turbine完成了战略投资。Turbine是一家AI细胞模拟公司，正在构建一个解释人体生物学的平台以加速药物开发。Turbine的核心技术Simulated Cell平台利用机器学习来了解人类细胞如何做出“决策”。该平台对细胞内和细胞周围的分子相互作用进行了复杂的建模，实现了在物理世界中几乎不可能实现的虚拟实验，并揭示了驱动疾病和对治疗产生响应的机制。据悉，Accenture的投资将帮助Turbine进一步将其能力扩展到全球生物医药公司，指导和加速关键的药物开发工作流程。读者们请星标⭐创鉴汇，第一时间收到推送免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文由药明康德内容团队根据公开资料整理编辑，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转发/复制至其他平台。转发授权请在「创鉴汇」微信公众号留言联系我们。更多数据内容推荐点击“在看”，分享创鉴汇健康新动态